Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
11.17
+0.19 (1.73%)
At close: Nov 21, 2025, 4:00 PM EST
11.13
-0.04 (-0.36%)
Pre-market: Nov 24, 2025, 7:00 AM EST
Kura Oncology Revenue
Kura Oncology had revenue of $20.75M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $104.03M. In the year 2024, Kura Oncology had annual revenue of $53.88M.
Revenue (ttm)
$104.03M
Revenue Growth
n/a
P/S Ratio
9.39
Revenue / Employee
$541,818
Employees
192
Market Cap
971.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KURA News
- 4 days ago - Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript - Seeking Alpha
- 10 days ago - Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia - GlobeNewsWire
- 10 days ago - US FDA approves Kura Oncology's blood cancer therapy - Reuters
- 11 days ago - Kura Oncology to Participate in Upcoming Investor Conference - GlobeNewsWire
- 16 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Kura Oncology Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 20 days ago - Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin - GlobeNewsWire